Who are TAKHZYRO's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orladeyo, BEROTRALSTAT HYDROCHLORIDE, Takhzyro, Kalbitor, C1 Esterase Inhibitor (Human), CINRYZE 1000.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lanadelumab-flyo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TAKHZYRO — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TAKHZYRO (LANADELUMAB-FLYO) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Plasma Kallikrein Inhibitor [EPC]. Area: Neuroscience.

marketed Plasma Kallikrein Inhibitor [EPC] Plasma kallikrein Neuroscience Live · refreshed every 30 min

Target snapshot

TAKHZYRO (LANADELUMAB-FLYO) — DYAX CORP..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAKHZYRO TARGET	LANADELUMAB-FLYO	DYAX CORP.	marketed	Plasma Kallikrein Inhibitor [EPC]	Plasma kallikrein
Orladeyo	BEROTRALSTAT	Biocryst	marketed	Plasma Kallikrein Inhibitor	Plasma kallikrein	2020-01-01
BEROTRALSTAT HYDROCHLORIDE	BEROTRALSTAT HYDROCHLORIDE		marketed		plasma kallikrein	2020-01-01
Takhzyro	LANADELUMAB	Dyax Corp	marketed	Plasma Kallikrein Inhibitor [EPC]	plasma kallikrein	2018-01-01
Kalbitor	ECALLANTIDE	Dyax Corp.	marketed	Plasma Kallikrein Inhibitor [EPC]	Plasma kallikrein	2009-01-01
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
CINRYZE 1000	CINRYZE 1000	Shire	phase 3	C1 esterase inhibitor (plasma-derived)	Plasma kallikrein; C1 esterase inhibitor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Plasma Kallikrein Inhibitor [EPC] class)

DYAX CORP. · 1 drug in this class
Dyax Corp · 1 drug in this class
Dyax Corp. · 1 drug in this class
Kalvista · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAKHZYRO — Competitive Intelligence Brief. https://druglandscape.com/ci/lanadelumab-flyo. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing